Moderna suffers setback in vaccine patent battle with Pfizer
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Hiltzik: A small study of COVID vaccine aftereffects triggers a political and scientific storm
Under normal circumstances, the study of health problems after COVID vaccinations posted online on Feb. 25 might not have generated much controversy.Its principal authors were well-respected ...
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
Infectious Disease Advisor5h
Updated COVID-19 mRNA-1273.815 Vaccine Effective in Adult Populations
The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.
mlive1d
Still ‘no red flags’ for COVID vaccine after years of monitoring their safety
Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...
IPWatchdog4d
Moderna COVID Vaccine Technology Struck Down by PTAB
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
MarketBeat on MSN1d
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.
5 years ago, the WHO declared COVID a pandemic. Here's a look at the disease by the numbers
Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million ...
JD Supra2d
COVID-19 Vaccine Patent War: Moderna's Claims Invalidated by PTAB
The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...
Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna's COVID sales have been declining, and the company has been trimming costs. But it doesn't have a huge growth ...
Among public companies, Covid created both winners and losers
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...
Long-term Brain Effects from COVID Vaccine Discussed in the Journal of American Physicians and Surgeons
The next-generation cost needs to be added to the long-term effects on vaccinees. Yet, Dr. Hatfill writes, the American College of Obstetrics and Gynecology (ACOG) has continued to promote the mass ...